Key result
NOAC uptake in AF patients climbs to ~30% over five years.
Cohort (n=1,545)
Yes
Absolute Event Rate: 29.8% vs 0%
p-value: p=<0.0001
The use of NOACs in Switzerland steadily increased to about 30% by 2015, accompanied by a significant reduction in aspirin monotherapy, reflecting improved guideline adherence for stroke prevention in atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Increasing NOAC use in Swiss AF may signal better guideline adherence; leaves open effects on stroke outcomes in real-world cohorts.
Zimny et al. (2017) conducted a cohort in atrial fibrillation (n=1,545). non-vitamin K antagonist oral anticoagulants (NOACs) vs. vitamin K antagonists (VKAs) or historical use in 2010 was evaluated on use of NOACs (p=<0.0001). The use of NOACs among patients with atrial fibrillation in Switzerland increased from 0% in 2010 to 29.8% in 2015 (p <0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: